Phase III data for narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy

In the single-arm open-label study (n=28), narsoplimab administered IV once-weekly was associated with a 61% (95% CI 40.6%-78.5%) complete response rate in the full analysis set (p<0.0001 compared to 15% efficacy threshold agreed with the FDA).

Source:

Biospace Inc.